FDA批准第一个抗PD1单抗？加速批准主要是基于 KEYNOTE-001 phase1b临床研究的结果?临床2,3期都未开始。似乎有不少PD-1的单抗药物在III期吧，这应该不是最快的，也不是第一个吧？ KEYTRUDA is the first anti-PD-1 (programmed death receptor-1) therapy approved in the United States and received FDA’s Breakthrough Therapy designation for advanced melanoma, which was granted based on the significance of early study findings and the unmet medical need. For the recommended 2 mg/kg dose based on data in 89 patients, the overall response rate was 24 percent (95% CI: 15, 34), with one complete response and 20 partial responses (21/89). At the time of analysis, 86 percent (18/21) of patients with objective responses had ongoing responses with durations ranging from 1.4+ to 8.5+ months, including eight patients with ongoing responses of 6 months or longer. Fourteen percent (3/21) had progression of disease 2.8, 2.9, and 8.2 months after initial response.查看更多
第1天
关注盖德视界
添加小助手
